Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care
Restricted accessResearch articleFirst published online 2026
Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care
Pomalidomide (POM) can cause skin rash, although it is generally considered less frequent than lenalidomide (LEN)-induced rash. However, skin rash remains a clinically relevant adverse event that may lead to treatment interruption in patients with multiple myeloma. This study aimed to identify clinical risk factors for POM-induced skin rash.
Methods
We retrospectively analyzed 76 patients who received POM-containing regimens between 2015 and 2022. The incidence, severity, and timing of skin rash were evaluated. Clinical variables were compared between patients with and without POM-induced skin rash, and multivariate logistic regression was performed to identify independent risk factors.
Results
POM-induced skin rash occurred in 22.4% of patients, with 17.1% experiencing Grade ≥2 rash. Treatment interruption due to rash occurred in 4 patients. A history of LEN-induced skin rash (p = 0.025) and no recent proteasome inhibitor exposure (p = 0.038) were identified as independent risk factors for POM-induced skin rash.
Conclusion
Patients with a prior history of LEN-induced skin rash or with long intervals since proteasome inhibitor exposure are at increased risk for POM-induced skin rash. Pharmacists should identify these high-risk patients before initiating POM therapy and implement early monitoring and supportive care to prevent unnecessary treatment interruption.
MorganGPalumboADhanasiriS, et al.Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol2015; 168: 820–823.
3.
SiegelDSSchillerGJSamarasC, et al.Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia2020; 34: 3286–3297.
4.
RichardsonPGOriolABeksacM, et al.Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol2019; 20: 781–794.
5.
AttalMRichardsonPGRajkumarSV, et al.Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet2019; 394: 2096–2107.
6.
DimopoulosMADytfeldDGrosickiS, et al.Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med2018; 379: 1811–1822.
7.
MoreauPMassziTGrzaskoN, et al.Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med2016; 374: 1621–1634.
8.
SuzukiKShinagawaAUchidaT, et al.Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci2016; 107: 653–658.
9.
TinsleySMKurtinSERidgewayJA, et al.Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk2015; 15: S64–S69.
10.
SugiTNishigamiYSaigoH, et al.Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma. Leuk Lymphoma2021; 62: 1405–1411.
11.
NardoneBWuSGardenBC, et al.Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk2013; 13: 424–429.
12.
HagiharaMIdeSOharaS, et al.Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization. Rinsho Ketsueki2019; 60: 137–139.
13.
BjorklundCCLuLKangJ, et al.Rate of CRL4(CRBN) substrate ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-myc and IRF4. Blood Cancer J2015; 5: e354.
14.
Lopez-GironaAMendyDItoT, et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia2012; 26: 2326–2335.
15.
PaivaBMateosMVSanchez-AbarcaLI, et al.Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood2016; 127: 1151–1162.
16.
GalustianCMeyerBLabartheMC, et al.The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother2009; 58: 1033–1045.
17.
OcioEMFernández-LázaroDSan-SegundoL, et al.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia2015; 29: 705–714.
18.
SehgalKDasRZhangL, et al.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood2015; 125: 4042–4051.
19.
RychakEMendyDShiT, et al.Pomalidomide in combination with dexamethasone results in synergistic anti-tumor responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol2016; 172: 889–901.
20.
SunamiKKomenoTSuzukiK, et al.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol2016; 5: 11.
21.
ShamrizOParnasaERubinL, et al.Desensitization protocol to lenalidomide: an effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma. Eur J Haematol2023; 110: 407–413.
22.
SugiTMitaMYasuT, et al.Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: case series. J Clin Pharm Ther2021; 46: 1792–1795.
23.
NakamuraAKimuraYTanakaY, et al.Favorable prognosis in patients with multiple myeloma and lenalidomide-induced skin rash: a multicenter retrospective study. Eur J Haematol2025; 114: 267–275.
24.
DoteSItoKItakuraS, et al.Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study. Leuk Lymphoma2019; 60: 2975–2981.
25.
PhanVItoTInabaM, et al.Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. Blood Adv2020; 4: 3572–3585.
26.
ScottGBCarterCParrishC, et al.Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Cell Immunol2015; 297: 1–9.
27.
SugiTMitaMYasuT, et al.Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash. J Clin Pharm Ther2022; 47: 477–482.
